We provide you with 20 years of free, institutional-grade data for PASG stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of PASG. Explore the full financial landscape of PASG stock.
| Reported Date | CIK | Ticker | Type |
|---|
Passage Bio, Inc(NASDAQ:PASG) 
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid b...
Website: http://www.passagebio.com
Founded: 2017
Full Time Employees: 20
CEO: Bruce A. Goldsmith
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about PASG stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.